GCP
NTLA icon

Gill Capital Partners’s Intellia Therapeutics NTLA Stock Holding History

Gill Capital Partners’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$169 Hold
10
– – ﹤0.01% 675
2026
Q1 		$128 Buy
+10
New +$127 ﹤0.01% 671

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Gill Capital Partners's NTLA Position: Q2 2026 in Review

Gill Capital Partners held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 10 shares worth $169. The position accounts for ﹤0.01% of the portfolio, ranked #675.

Gill Capital Partners first reported a position in NTLA in Q1 2026 and has held it in 2 quarters since. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Gill Capital Partners held 10 shares of Intellia Therapeutics worth $169 as of Q2 2026.
  • Gill Capital Partners left its Intellia Therapeutics share count unchanged in Q2 2026.
  • Intellia Therapeutics made up ﹤0.01% of Gill Capital Partners's portfolio in Q2 2026, its #675 holding.
  • Gill Capital Partners first reported a position in Intellia Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Gill Capital Partners's 13F filing for Q2 2026, filed 20 Aug 2026.